Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

Roswell Park Experts to Showcase Groundbreaking Hematology Research at 66th ASH Annual Meeting

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

FDA Approves Companion Diagnostic for Zanidatamab in HER2+ Biliary Tract Cancer

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

ASH Annual Meeting and Exposition

Latest Conference Coverage